DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab

Information source: University Health Network, Toronto
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Wet Macular Degeneration

Intervention: Ranibizumab (Drug); Triamcinolone Acetonide (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: University Health Network, Toronto

Official(s) and/or principal investigator(s):
Wai-Ching Lam, MD, FRCSC, Principal Investigator, Affiliation: University Health Network, Toronto Western Hospital

Overall contact:
Wai-Ching Lam, MD, FRCSC, Phone: (416) 603-5376, Email: waiching.lam@utoronto.ca


In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments. ARMD is related to the body initiating an immune response in the eye, as if responding to an infection. Vision is impacted as ocular tissue becomes inflamed and new blood vessels form at the back of the eye, a process called angiogenesis. In the more severe wet form of ARMD, blood and fluid leak out of the vessels and impair the eye's structure and function. Many studies have shown that ranibizumab, a drug that stops the formation of new blood vessels (an anti-angiogenic agent) can delay damage to the eye and often restore vision. The investigators believe the best drug therapy will also stop the inflammation. Triamcinolone acetonide, a steroid drug, has shown the potential to effectively reduce inflammation in this application. The investigators aim to investigate if patients receiving a combination treatment of ranibizumab and triamcinolone acetonide improve their visual abilities more than those receiving just ranibizumab treatment alone. Secondarily, the investigators will also investigate how often patients receiving each drug therapy regime require re-treatment and how often they experience further vision loss.

Clinical Details

Official title: Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Gains in visual acuity

Secondary outcome:

Changes in intra-ocular pressure

Rates of re-treatment

Rate of vision loss

Rate of cataract progression

• Changes in choroid vessel activity in lesion growth and activity at choroid

Detailed description: Age Related Macular Degeneration (ARMD or AMD) is the leading cause of blindness in North America. There are two types of ARMD: dry and wet. Both forms of ARMD cause a progressive loss of central vision, the part of your vision that allows you to read, drive and see images in sharp detail directly in front of you. The wet form is typically more severe and is characterized by the growth and leakage of small blood vessels into the choroid layer of the eye, or the back of the eye. These leaking blood vessels disrupt the structure and function of the eye, causing loss of vision, particularly the sharp vision created by the macula area of the eye. Upon being accepted to the study, participants will be randomly divided into two groups. One group will receive both ranibizumab and triamcinolone acetonide injections and the other group will receive ranibizumab injections and a placebo treatment. To participants in this group, there will be the appearance of a second injection but no actual injection will take place. An individual not connected to the study will assign participants to a group based on a computer-generated system, giving participants at 50% chance of being placed in either group. During the study, participants will not know which group they are in, but will be able to know once the study is finished. Participants will be asked to come in for an initial assessment to determine their starting visual abilities and medical history. On the next appointment, participants will receive the first treatment injections. They will be asked to come into the clinic every month for six (6) months total for treatment injections and testing. At each appointment, study investigators will take 3-D images of the retina (the back of the eye) using an Optical Coherence Tomography (OCT) imaging device, test eye pressure and determine if there are any signs of infection or inflammation from the injections. On months 1, 3 and 6 investigators will also test vision using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts, contrast sensitivity using a standard contrast sensitivity chart (The Pelli-Robson chart) and take images of the blood vessel growth using a coloured dye (fluorescein) to help see blood vessels. Before every treatment, anesthetic eye drops (proparacaine) will be applied to the eye so participants will not feel the injections. Participants will be given antibiotic eye drops (Zymar®) and will be asked to apply the drops 4 times a day for a few days after the injection to prevent infection.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patients with wet age-related macular degeneration (ARMD) with evidence of sub-foveal

choroidal neo-vascularization (CNV)

- Patients greater than the age 18 years old (male or female)

- Visual acuity must be between 20/40 and 20/320 in the study eye.

Exclusion Criteria:

- Patients with CNV from causes other than ARMD

- Patients having intra-ocular surgery within past 3 months on study eye

- Patients with medically uncontrolled glaucoma

- Patients with prior vitreous/retinal surgery

- Patients with a history of past CNV treatment in study eye

- Patients with other ocular conditions causing vision loss that could confound the

analysis of ARMD

- Individuals with a disability preventing accurate vision testing

Locations and Contacts

Wai-Ching Lam, MD, FRCSC, Phone: (416) 603-5376, Email: waiching.lam@utoronto.ca

University Health Network-Toronto Western Hospital, Toronto, Ontario M5T 2S8, Canada; Recruiting
Wai-Ching Lam, MD, FRCSC, Phone: 416-603-5376, Email: waiching.lam@utoronto.ca
Emmanuel Mavrikakis, MD, PhD, Sub-Investigator
Robert Devenyi, MD, FRCSC, Sub-Investigator
Sourabh Arora, BSc, Sub-Investigator
Laura Schneider, BSc, Sub-Investigator
Additional Information

Related publications:

Chaudhary V, Mao A, Hooper PL, Sheidow TG. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology. 2007 Dec;114(12):2183-9.

Starting date: January 2011
Last updated: February 8, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017